Loading...
XHKG0867
Market cap2.31bUSD
Dec 23, Last price  
7.42HKD
1D
0.13%
1Q
-11.03%
Jan 2017
-39.58%
IPO
166.91%
Name

China Medical System Holdings

Chart & Performance

D1W1MN
XHKG:0867 chart
P/E
7.02
P/S
2.10
EPS
0.99
Div Yield, %
7.59%
Shrs. gr., 5y
-0.28%
Rev. gr., 5y
8.08%
Revenues
8.01b
-12.43%
293,521,292378,015,974495,420,948658,586,947876,679,8131,322,320,0051,759,354,0172,201,418,5412,945,131,0003,553,431,0004,900,812,0005,348,838,0005,433,449,0006,073,624,0006,945,964,0008,337,221,0009,150,347,0008,013,285,000
Net income
2.40b
-26.33%
31,299,16563,444,619101,991,205141,230,145202,871,947391,404,660530,797,280623,144,1781,045,702,000995,935,0001,375,936,0001,674,807,0001,849,883,0001,960,712,0002,530,398,0003,017,402,0003,258,992,0002,400,940,000
CFO
2.50b
-29.56%
62,309,82248,008,98569,433,996106,168,41674,225,650394,346,040435,615,919327,749,899843,198,000614,552,0001,067,880,0002,071,798,0001,754,565,0002,555,119,0002,692,027,0002,493,852,0003,553,243,0002,502,853,000
Dividend
Aug 29, 20240.164 HKD/sh
Earnings
Mar 25, 2025

Profile

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
URL
https://web.cms.net.cn/zh/home/
IPO date
Sep 28, 2010
Employees
5,622
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,013,285
-12.43%
9,150,347
9.75%
8,337,221
20.03%
Cost of revenue
5,267,222
5,597,855
5,186,186
Unusual Expense (Income)
NOPBT
2,746,063
3,552,492
3,151,035
NOPBT Margin
34.27%
38.82%
37.79%
Operating Taxes
489,341
486,655
431,325
Tax Rate
17.82%
13.70%
13.69%
NOPAT
2,256,722
3,065,837
2,719,710
Net income
2,400,940
-26.33%
3,258,992
8.01%
3,017,402
19.25%
Dividends
(1,360,363)
(1,276,239)
(1,154,834)
Dividend yield
4.01%
4.24%
3.59%
Proceeds from repurchase of equity
1,272,228
(203,338)
BB yield
-4.22%
0.63%
Debt
Debt current
1,285,066
1,799,141
1,120,682
Long-term debt
48,758
42,786
626,355
Deferred revenue
163,704
Other long-term liabilities
909
736
Net debt
(8,424,368)
(7,807,889)
(6,404,756)
Cash flow
Cash from operating activities
2,502,853
3,553,243
2,493,852
CAPEX
(27,490)
(524,921)
(184,841)
Cash from investing activities
(442,276)
(1,178,202)
(1,519,525)
Cash from financing activities
(2,125,024)
(1,399,914)
(258,392)
FCF
3,449,074
2,773,614
1,078,541
Balance
Cash
6,143,316
5,867,712
4,363,613
Long term investments
3,614,876
3,782,104
3,788,180
Excess cash
9,357,528
9,192,298
7,734,932
Stockholders' equity
13,258,795
14,392,445
13,121,975
Invested Capital
7,500,616
6,969,183
6,645,459
ROIC
31.19%
45.04%
45.17%
ROCE
16.18%
21.81%
21.73%
EV
Common stock shares outstanding
2,451,989
2,453,940
2,467,697
Price
13.84
12.70%
12.28
-5.68%
13.02
48.97%
Market cap
33,935,521
12.61%
30,134,386
-6.21%
32,129,409
48.72%
EV
25,547,352
22,587,217
25,854,833
EBITDA
2,975,628
3,779,718
3,370,855
EV/EBITDA
8.59
5.98
7.67
Interest
46,251
49,086
28,270
Interest/NOPBT
1.68%
1.38%
0.90%